US Stock MarketDetailed Quotes
FGEN FibroGen
- 0.392
- -0.004-0.89%
Close Oct 18 16:00 ET
- 0.402
- +0.011+2.73%
Post 19:59 ET
39.31MMarket Cap-230P/E (TTM)
0.402High0.375Low862.91KVolume0.395Open0.395Pre Close337.11KTurnover0.95%Turnover RatioLossP/E (Static)100.40MShares2.93052wk High-0.17P/B35.44MFloat Cap0.30152wk Low--Dividend TTM90.52MShs Float68.550Historical High--Div YieldTTM6.76%Amplitude0.301Historical Low0.390Avg Price1Lot Size
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data
FibroGen Stock Forum
hope you can perform again 💪💪💪
FibroGen Inc - Study Did Not Meet Primary Endpoint
FibroGen, Inc. (NASDAQ:FGEN) recently announced a milestone in its oncology pipeline. The U.S. Food and Drug Administration (FDA) has cleared the Company's Investigational New Drug (IND) application for FG-3165, a novel galectin-9 (Gal9) targeted monoc...
FibroGen Announces FDA Clearance of Investigational New Drug Application for FG-3165, a Galectin-9 Targeting Monoclonal Antibody, for the Treatment of Patients with Solid Tumors
FibroGen (NASDAQ: FGEN) announced FDA clearance for its Investigational New Drug (IND) application for FG-3165, a monoclonal antibody targeting galectin-9 (Gal9) for treating solid tumors. FG-3165 has shown anti-tumor activity and improved survival in preclinical models and exhibited excellent tol...
FibroGen Announces Clinical Trial Supply Agreement With Regeneron Pharmaceuticals to Evaluate Fibrogen’s Immuno-Oncology Assets, FG-3165 (Anti-Galectin 9) and FG-3175 (Anti-Ccr8), in Combination With Libtayo® in Upcoming Clinical Trials
No comment yet